Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A registrational study of ARGX-119, a first-in-class agonist antibody to muscle-specific kinase (MuSK) in patients with congenital myasthenic syndromes (CMS)

Next Previous
Trial Profile

A registrational study of ARGX-119, a first-in-class agonist antibody to muscle-specific kinase (MuSK) in patients with congenital myasthenic syndromes (CMS)

Status: Planning
Phase of Trial: Phase III

Latest Information Update: 21 Aug 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs ARGX-119 (Primary)
  • Indications Congenital myasthenic syndromes
  • Focus Registrational; Therapeutic Use

Most Recent Events

  • 31 Jul 2025 According to an argenx media release, Registrational study to start in CMS in 2026 following positive Phase 1b proof-of-concept data
  • 08 Jul 2025 New trial record
  • 30 Jun 2025 According to an argenx media release, the decision to advance the development of ARGX-119 in CMS to a registrational study is supported by the results of the Phase 1b study

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top